Skip to main content
Journal ArticleOPEN ACCESS

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy

  • Esfahani K
  • Hudson M
  • Batist G
New England Journal of Medicine (2020) 382(24) 2374-2375
DOI: 10.1056/nejmc2002527
62Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

Tofacitinib for Autoimmune Colitis from Anti-PD1 Tofacitinib is a JAK inhibitor that decreases cytokine production. In a woman with autoimmune colitis from the administration of pembrolizumab to tr...

Cite

CITATION STYLE

APA

Esfahani, K., Hudson, M., & Batist, G. (2020). Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. New England Journal of Medicine, 382(24), 2374–2375. https://doi.org/10.1056/nejmc2002527

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free